【摘要】 目的观察唑来膦酸治疗原发性骨质疏松症的临床疗效及安全性。方法应用唑来膦酸注射液治疗35例57～85岁原发性骨质疏松症患者,分别观察治疗前后患者骨痛的缓解情况、血钙、磷、碱性磷酸酶、骨钙素、尿DPD/Cr变化情况。采用双能X线骨密度仪测定患者治疗前后骨密度。观察患者治疗后不良反应的发生情况。结果全部患者骨痛症状明显改善,总优良率达100%。血钙、磷、碱性磷酸酶、骨钙素无显著变化,尿DPD/Cr较治疗前显著降低(P<0.01)。骨密度较治疗前显著增加(P<0.01),35例患者均无明显不良反应发生。结论唑来膦酸是治疗原发性骨质疏松症的安全有效性药物。更多还原

【Abstract】 Objective To observe the efficacy and safety of zoledronic acid for the treatment of primary osteoporosis.Methods Thirty-five primary osteoporosis patients aged from 57 to 85 years old were treated with 5mg zoledronic acid.The mitigation of pains and the variation of serum calcium,phosphate,alkaline phosphatase,and urine DPD/Cr were observed before and after the treatment.BMD was measured using dual energy X-ray absorptionmetry(DXA).The incidence of adverse reactions after the treatment was observed.Results Pain was significantly ameliorated in all patients and the total excellent and good rate was 100%.The result of serum calcium,phosphorus,alkaline phosphatase,and BGP showed no significant change.The result of urinary DPD/Cr after the treatment was significantly lower than that before the treatment(P<0.01).BMD was significantly lower than that before the treatment(P<0.01).No obvious adverse reactions happened in all 35 patients.Conclusion Zoledronic acid is an effective and safe drug for the treatment of primary osteoporosis.更多还原